Additionally, using multivariate Cox models adjusted for patients’ gender, age, smoking status, tumor histology and response to previous treatment, CD3-TIL low (HR = 0.381; 95% CI: 0.181–0.799; p = 0.011), CD8-TIL low (HR = 0.388; 95% CI: 0.182–0.830; p = 0.015) and GZMB-TIL low (HR = 0.173; 95% CI: 0.058–0.520; p = 0.002) emerged as independent predictive factors associated with improved OS in patients treated with Vx-001 (Table 2). The gene discussed is CD8A; the disease is neoplasm.